Dear Germaine, Dasatinib is working great for you! You are only 10%Ph+ and you had not achieved remission on Gleevec. That is great news.
Rob is very right, chromosomal abnormalities in cells not having the Ph chromosome are not so worrisome. From articles I have read, doctors say that these additional chromosomal abnormalities can be present with the Ph chromosome but when the Ph chromosome percentage goes down due to the targeted approach of Gleevec/Dasatinib, this can give a selective advantage to cells with abnormal chromosomes to grow. There have been many studies on chromosome abnormalities that crop up on Gleevec patients. It is called Ph negative clonal evolution since these abnormalities occur in cells not having the Ph chromosome. The incidence with Gleevec is around 10% so not very common. Many of the patients who have these abnormalities have seen them disappear over time, they are transient and disappear with further therapy. What doctors do, however, is monitor these patients by doing periodic BMAs and the reason for that is that a small percentage of patients having these abnormalities, especially monosomy 7, have developed different diseases like myelodysplastic syndrome (MDS) and acute leukemia. Monosomy 7 is one chromosome 7 missing. Trisomy 8 is an extra copy of chromosome 8. I personally know two patients who had more than your percentage of Trisomy 8 and with therapy, these percentages are going down and for one patient, it is completely gone. There is no reason for Dasatinib not to behave similarly, it is a stronger targeted therapy than Gleevec. Since Dasatinib is very new, articles on the drug are just coming out. I have been helping the BMS trial patients in our clinic and quite a few of them had trisomy 8 and it disappeared on therapy. Below, I give the most recent Ph negative clonal evolution article which happens to be from Canada. Here is a study of 141 Canadian patients during Gleevec therapy. The incidence of patients who developed chromosomal abnormalities other than the Ph chromosome is only 8.7% in 3 years follow-up so it is relatively rare as also seen from worldwide studies. The Canadian patients who developed the abnormalities, 7 had either monosomy 7 (loss of chromosome 7) or trisomy 8 (extra copy of chromosome 8), 1 had a loss of X chromosome and chromosome 22 and 1 had a translocation between chromosomes 12 and 16. 2 patients presented with same chromosomal abnormality in Ph negative and positive cells. The emergence of the abnormalities occurred median 13.3 months after the start of Gleevec. This may follow from the hypothesis that small amounts of these abnormalities may be present at start of therapy and after Gleevec reduces the phillies, these abnormalities give a selective growth to cells with the abnormal chromosomes which proliferate. Patients who took Gleevec 1 year after diagnosis or less had more risk of developing these abnormalities. None of the patients who developed the abnormalities developed myelodysplasia. And there was no difference in event-free survival on Gleevec in these patients compared to those who did not have the abnormalities. So, the authors conclude that even though the development of chromosomal abnormalities are rare, they may occur more on Gleevec therapy than on other CML therapies but do not confer a worse prognosis. I have given the article below. Here are two things you can now do: 1. It does seem to me that your doctors may not have many cases of trisomy 8. OHSU has a database for Gleevec patients having chromosomal abnormalities. Maybe, this is an opportune time to consult with Dr. Brian Druker and have his feedback on your options. OHSU keeps a database on patients who develop chromosomal abnormalities on Gleevec. I know you are very much wanting to consult there, please do convince your Mom that now may be the time. You want the best medical advice from a CML expert and not be rushed into a BMT. 2. Your doctors can ask Bristol-Myers-Squibb about the incidence of chromosomal abnormalities on Dasatinib and what is recommended. Germaine, I am looking at the broader picture, you are responding well to Dasatinib, achieving remission with a drug when Gleevec did not do that job. Odds are that the chromosomal abnormalities will disappear but do take the medical opinion of OHSU experts on this, they have a broad experience on Gleevec and Dasatinib is a stronger inhibitor. Avail of all medical expert opinions on drug therapy and only then consult for transplant. Seems to me you are doing very well on Dasatinib. Warm Wishes, Anjana caregiver to Roy : Cancer Genet Cytogenet. 2006 Oct 1;170(1):16-23. Links Philadelphia-negative clonal hematopoiesis following imatinib therapy in patients with chronic myeloid leukemia: a report of nine cases and analysis of predictive factors. a.. Lin Y, b.. Bruyere H, c.. Horsman DE, d.. Pantzar T, e.. Barnett MJ, f.. Hogge DE, g.. Nevill TJ, h.. Nantel SH, i.. Sutherland HJ, j.. Toze CL, k.. Shepherd JD, l.. Lavoie JC, m.. Song KW, n.. Smith CA, o.. Forrest DL. The Leukemia/BMT Program of British Columbia, the Division of Hematology, 950 West 10th Avenue, Room 3300, Vancouver, British Columbia V5Z 4E3, Canada. There are increasing reports of Philadelphia-negative (Ph-negative) clonal hematopoiesis developing among patients with chronic myeloid leukemia (CML) treated with imatinib mesylate (IM). To establish the incidence and significance of these chromosomal abnormalities, we analyzed data on 141 consecutive patients with CML treated with IM at the British Columbia Cancer Agency and Vancouver General Hospital from 1999 to 2004. The cumulative incidence of developing a Ph-negative clone three years from the start of IM was 8.7% at a median of 13.3 months. The Ph-negative clonal abnormalities included monosomy 7 and/or trisomy 8 (seven patients), monosomy for chromosomes X and 22 (one patient), and a (12;16) translocation (one patient). Two of the patients presented with the same chromosomal abnormality in both Ph-negative and Ph-positive cells. None of the Ph-negative clonal abnormalities was associated with myelodysplasia. In a multivariate analysis, an interval from diagnosis to initiation of IM of 1 year or less was associated with an increased risk of developing a Ph-negative clone (relative risk = 20.2; P = 0.025). There was no difference, however, in event-free survival between patients who did and did not develop Ph-negative clones. Therefore, while the development of Ph-negative clonal hematopoiesis in patients with CML treated with IM is uncommon, it appears to be more frequent than that previously seen with IFN, but it does not seem to confer a worse prognosis. --~--~---------~--~----~------------~-------~--~----~ [CMLHope] A support group of http://cmlhope.com ------------------------------------------------- You received this message because you are subscribed to the Google Groups "CMLHope" group. To post to this group, send email to [email protected] To unsubscribe from this group, send email to [EMAIL PROTECTED] For more options, visit this group at http://groups.google.com/group/CMLHope -~----------~----~----~----~------~----~------~--~---

